What question did this study set out to answer?

The study aims to evaluate the efficacy of SM08502 in combination with PARP inhibitors to overcome resistance in high-grade serous carcinoma.

December 8, 2025Cancer Research CommunicationsOpen Access

SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

View Full Paper

Ask AI

Bookmark

Authors

BCBradley R. Corr EWElizabeth R. Woodruff TYTomomi M. Yamamoto

Discussion

Member takes

Implication

Preclinical evidence shows SM08502 reduces tumor progression and enhances survival in HGSC with PARP inhibitor resistance, implicating WNT signaling and immune microenvironment alterations.

Key Points

The study aims to evaluate the efficacy of SM08502 in combination with PARP inhibitors to overcome resistance in high-grade serous carcinoma.
Tested an indirect WNT inhibitor, SM08502, in PARP-resistant HGSC models.
Analyzed TCF transcriptional activity, gene expression, and tumor microenvironment using multispectral IHC.
Evaluated the efficacy of SM08502/olaparib combination in vivo using immune-compromised and immune-intact models.
SM08502 inhibits WNT/TCF transcriptional activity and induces DNA damage in resistant models.
Combined treatment significantly reduces tumor progression and remodels the tumor immune microenvironment.
Treatment lowers immune-suppressive PD-1 and PD-L1 expression, extending survival.

Cite This Study

Corr et al. (2025) studied this question.

synapsesocial.com/papers/693624a44fa91c937236c3d2 https://doi.org/10.1158/2767-9764.crc-25-0267

View Full Paper

Ask AI

Bookmark

Implication

Preclinical evidence shows SM08502 reduces tumor progression and enhances survival in HGSC with PARP inhibitor resistance, implicating WNT signaling and immune microenvironment alterations.

SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

Discussion

Member takes

Implication

Key Points

Cite This Study

SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider